Dasiglucagon is a 29-amino-acid analog of glucagon that raises blood sugar. FDA approved it in 2021 as Zegalogue for severe hypoglycemia in people with diabetes. This guide covers its structure, mechanism, label, key trials and regulatory status, using sources checked on November 17, 2026.
Quick answer: Dasiglucagon is a modified form of the hormone glucagon and a prescription drug. It acts on liver glucagon receptors to raise blood glucose. Its brand is Zegalogue, and Drugs@FDA now lists both Zegalogue products as discontinued.
Vitrapep does not sell dasiglucagon; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is dasiglucagon?
Dasiglucagon is a glucagon analog, a modified version of the natural hormone. The Zegalogue label describes it as “comprised of 29 amino acids” and calls it a glucagon analog and an antihypoglycemic agent. Trial authors describe it as “stable in aqueous formulation” (Pieber et al., 2021b). As a short amino acid chain, it is a peptide. Our overview of peptide hormones covers the family it belongs to.
PubChem lists the molecular formula as C152H222N38O50 and the molecular weight as 3381.6 g/mol (PubChem). The label gives the same formula and a molecular mass of 3382 g/mol. FDA approved dasiglucagon on March 22, 2021, as Zegalogue. Drugs@FDA classes it as a new molecular entity, and Zealand Pharma holds the application.
Dasiglucagon: key facts
| Fact | Detail |
|---|---|
| Structure | Peptide of 29 amino acids; a modified analog of glucagon |
| Class | Glucagon receptor agonist; antihypoglycemic agent |
| Molecular formula | C152H222N38O50 |
| Molecular weight | 3381.6 g/mol (PubChem) |
| First FDA approval | March 22, 2021 (new molecular entity) |
| Approved brands | Zegalogue (both products now listed as discontinued in Drugs@FDA) |
How does dasiglucagon work?
Dasiglucagon works like glucagon. The label calls it “a glucagon receptor agonist, which increases blood glucose concentration.” It activates glucagon receptors in the liver. That signal makes the liver break down stored glycogen and release glucose into the blood.
The effect depends on glycogen stores. The label states that dasiglucagon helps only when the liver holds enough glycogen. It names starvation, adrenal insufficiency and chronic hypoglycemia as states where stores may run short. The label also reports that dasiglucagon is cleared like native glucagon, by protein breakdown in blood, liver and kidney. It gives a half-life of about 30 minutes. Our explainer on peptide half-life covers how such clearance is measured.
What is dasiglucagon approved for?
The current Zegalogue label, revised in June 2026, has one indication. Zegalogue “is indicated for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes who weigh at least 20 kg” (Zegalogue label, 2026).
Earlier labels were narrower. The January 2023 version on DailyMed covers patients with diabetes “aged 6 years and above.” FDA approved the change on June 18, 2026. The approval letter says it rests on a Phase 3 open-label trial in children below 6 years of age with type 1 diabetes.
What did the key trials of dasiglucagon show?
All three trials below were in people. The first two supported approval; the third tested an unapproved use.
Adult pivotal trial. NCT03378635 randomized 170 adults with type 1 diabetes to dasiglucagon, placebo or glucagon. The trial was double-blind, and low blood sugar was induced with insulin. The primary endpoint was time to a set rise in plasma glucose. Median time was 10 minutes with dasiglucagon, versus 40 minutes with placebo (P < 0.001). It was 12 minutes with glucagon. Within 15 minutes, 99% of the dasiglucagon group recovered, versus 2% with placebo and 95% with glucagon (Pieber et al., 2021a). The label notes there was no formal statistical test against glucagon.
Pediatric pivotal trial. NCT03667053 randomized 42 children and adolescents, aged 6 to 17, with type 1 diabetes. Median time to recovery was 10 minutes with dasiglucagon, versus 30 minutes with placebo (P < .001). Glucagon also took 10 minutes. Everyone given dasiglucagon or glucagon recovered within 20 minutes, versus 2 of 11 given placebo (Battelino et al., 2021).
Congenital hyperinsulinism trial. A randomized, open-label Phase 3 trial enrolled 32 children with congenital hyperinsulinism, aged 0.6 to 10.9 years (Thornton et al., 2024). It compared standard care alone with standard care plus dasiglucagon. The primary endpoint, low-glucose episodes per week on self-monitored glucose checks, was not met (rate ratio 0.85, P = .5028). A post hoc analysis of continuous glucose monitor data found 43% fewer low-glucose events. Skin and gastrointestinal events were more frequent with dasiglucagon.
What side effects does the dasiglucagon label list?
The Zegalogue label has no boxed warning. In two placebo-controlled adult trials, 116 adults received dasiglucagon and 53 received placebo. The label lists nausea (57% versus 4%), vomiting (25% versus 2%) and headache (11% versus 4%). Diarrhea (5% versus 0%) and local site pain (2% versus 0%) follow. In the pediatric trial of 20 treated children, rates were nausea 65%, vomiting 50%, headache 10% and local site pain 5%.
The label lists other reactions within 12 hours, including high and low blood pressure, slow heart rate and palpitations. Warnings cover pheochromocytoma, insulinoma, allergic reactions and low liver glycogen. Dasiglucagon is contraindicated in pheochromocytoma and insulinoma. The label also reports that 4 of 506 people (<1%) given dasiglucagon developed antibodies against it.
What is the regulatory status of dasiglucagon, and is it used in research?
Dasiglucagon is a prescription drug. Drugs@FDA, checked November 17, 2026, lists both Zegalogue products with a “Discontinued” marketing status. FDA still approved a labeling supplement on June 18, 2026. That update also added a 26-week mouse study in which dasiglucagon was not carcinogenic. Those are animal data.
FDA’s Drug Safety Communications page, current as of November 9, 2026, lists no communication about dasiglucagon. WADA’s 2026 Prohibited List does not name it. See our guide to the 2026 WADA list.
We found no FDA approval of dasiglucagon for congenital hyperinsulinism; the June 2026 Zegalogue label covers diabetes only. Zealand Pharma announced on October 9, 2024 that FDA had issued a complete response letter for that use. The company said the letter concerned the timing of a reinspection at a third-party manufacturing site. It said the letter raised no concerns about the clinical data or safety. Researchers have also tested dasiglucagon in other low-blood-sugar conditions. In a 10-person crossover trial in people with low blood sugar after gastric bypass surgery, it raised the lowest glucose reading versus placebo (Nielsen et al., 2022).
Frequently asked questions about dasiglucagon
Is dasiglucagon a peptide?
Yes. It is a chain of 29 amino acids, a modified analog of glucagon. See our guide to types of peptides.
Is dasiglucagon the same as glucagon?
No. It is a separate molecule with a different formula. It acts on the same liver receptor. Our glucagon guide covers the natural hormone.
When was dasiglucagon approved?
FDA approved it on March 22, 2021, as Zegalogue. A label update followed on June 18, 2026.
Is dasiglucagon approved for congenital hyperinsulinism?
We found no FDA approval for that use. A Phase 3 trial in children missed its primary endpoint, and the company reported an FDA complete response letter in October 2024.
Does Zegalogue have a boxed warning?
No. The most common reactions in adults were nausea, vomiting and headache.
What to know now
- Structure: 29-amino-acid glucagon analog; 3381.6 g/mol.
- Mechanism: activates liver glucagon receptors, releasing stored glucose.
- Approval: Zegalogue, March 22, 2021; label updated June 18, 2026.
- Trials: median recovery of 10 minutes versus 40 (adults) and 30 (children) with placebo.
- Safety: no boxed warning; nausea and vomiting are the most common reactions.
- Status: both Zegalogue products listed as discontinued; no FDA approval found for congenital hyperinsulinism.
What we’re watching
Any FDA action on dasiglucagon for congenital hyperinsulinism after the October 2024 complete response letter. Whether Zegalogue returns to an active marketing status, and when DailyMed posts the June 2026 label. And the Phase 3 trial NCT06588504 in Asian adults with type 1 diabetes, whose results were first posted on November 16, 2026.